Akron Biotech and Vivex Biomedical, Inc. have just announced a strategic collaboration on the use of Akron’s next-generation line of cryopreservation media, CryoNovo™ in one of Vivex’ therapeutic applications.
CryoNovo™ is Akron’s brand new range of DMSO-free cryopreservation media. Developed to meet the growing needs for efficient cryopreservation of a variety of cells, the CryoNovo™ line includes three products, each tailored to a specific application:
- CryoNovo™ X12 – for the preservation of specialized biological cells
- CryoNovo™ P24 – for the preservation of mesenchymal stem cells
- CryoNovo™ T82 – for the preservation of biological cells
CryoNovo™ media are DMSO-, serum- and glycerol- free. They are also non-toxic and developed from completely natural components.
In the collaboration, Akron’s CryoNovo™ T82 is used in the Vivex process of viable bone allograft preparation.